文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT 显像肿瘤间质以提高原发灶不明头颈癌原发肿瘤诊断准确性的比较影像学试验

Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
PubMed 文献 · J Nucl Med · 2024-03-01

这项前瞻性比较影像学试验纳入91例综合临床检查及常规影像原发灶阴性或可疑的头颈癌原发灶不明患者,比较68Ga-FAPI PET/CT与18F-FDG PET/CT检测原发灶的能力。68Ga-FAPI PET/CT检出原发灶46个,多于18F-FDG PET/CT的17个(P<0.001),敏感性、阳性预测值和准确性均更高,并使22/91(24%)患者治疗方案发生改变。

要点

  • 68Ga-FAPI PET/CT检出原发灶46个,18F-FDG PET/CT检出17个,差异有统计学意义(P<0.001)。
  • 68Ga-FAPI PET/CT敏感性51%、阳性预测值98%、准确性51%,18F-FDG PET/CT分别为25%、43%、19%。
  • 68Ga-FAPI PET/CT使22/91(24%)患者治疗方案发生改变。

核心结论

  • 68Ga-FAPI PET/CT在检测头颈癌原发灶不明患者原发病灶方面优于18F-FDG PET/CT,作者认为其可作为敏感、可靠且可重复的显像方法用于该类患者。

研究设计与样本

  • 前瞻性比较影像学试验,在复旦大学附属肿瘤医院开展,2020年6月至2022年9月纳入91例综合临床检查及常规影像原发灶阴性或可疑的头颈癌原发灶不明患者。
  • 由3名经验丰富的核医学医师记录原发灶存在情况,原发病灶经组织病理学分析和复合参考标准验证。

主要发现

  • 91例患者中(女18例、男73例;中位年龄60岁,年龄范围24~76岁),经全面诊断检查后46例(51%)检出原发肿瘤。
  • 68Ga-FAPI PET/CT检出原发灶46个,18F-FDG PET/CT检出17个(P<0.001)。
  • 68Ga-FAPI PET/CT定位原发灶的敏感性为51%、阳性预测值为98%、准确性为51%,18F-FDG PET/CT分别为25%、43%、19%。
  • 68Ga-FAPI PET/CT使91例中22例(24%)患者治疗方案发生改变,18F-FDG PET/CT为对照。
  • Kaplan-Meier曲线显示,未识别原发肿瘤的患者预后显著差于已识别原发肿瘤的患者(风险比5.77;95%CI 1.86~17.94;P=0.0097)。

关键数值与推荐

  • 68Ga-FAPI PET/CT检出原发灶46个 vs 18F-FDG PET/CT 17个(P<0.001)。
  • 68Ga-FAPI PET/CT敏感性51% vs 18F-FDG PET/CT 25%。
  • 68Ga-FAPI PET/CT阳性预测值98% vs 18F-FDG PET/CT 43%。
  • 68Ga-FAPI PET/CT准确性51% vs 18F-FDG PET/CT 19%。
  • 未识别原发肿瘤患者预后风险比为5.77(95%CI 1.86~17.94;P=0.0097)。

临床怎么用

  • 作者认为68Ga-FAPI PET/CT在检测原发病灶方面优于18F-FDG PET/CT,可作为敏感、可靠且可重复的显像方法用于头颈癌原发灶不明患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The low detection rate of primary tumors by current diagnostic techniques remains a major concern for patients with head and neck cancer of unknown primary (HNCUP). Therefore, in this study, we aimed to investigate the potential role of 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT compared with 18F-FDG PET/CT for the detection of primary tumors of HNCUP. Methods: In this prospective comparative imaging trial conducted at Fudan University Shanghai Cancer Center, 91 patients with negative or equivocal findings of a primary tumor by comprehensive clinical examination and conventional imaging were enrolled from June 2020 to September 2022. The presence of a primary tumor was recorded by 3 experienced nuclear medicine physicians. Primary lesions were validated by histopathologic analysis and a composite reference standard. Results: Of the 91 patients (18 women, 73 men; median age, 60 y; age range, 24-76 y), primary tumors were detected in 46 (51%) patients after a thorough diagnostic work-up. 68Ga-FAPI PET/CT detected more primary lesions than 18F-FDG PET/CT (46 vs. 17, P < 0.001) and showed better sensitivity, positive predictive value, and accuracy in locating primary tumors (51% vs. 25%, 98% vs. 43%, and 51% vs. 19%, respectively). Furthermore, 68Ga-FAPI PET/CT led to treatment changes in 22 of 91 (24%) patients compared with 18F-FDG PET/CT. The Kaplan-Meier curve illustrated that patients with unidentified primary tumors had a significantly worse prognosis than patients with identified primary tumors (hazard ratio, 5.77; 95% CI, 1.86-17.94; P = 0.0097). Conclusion: 68Ga-FAPI PET/CT outperforms 18F-FDG PET/CT in detecting primary lesions and could serve as a sensitive, reliable, and reproducible imaging modality for HNCUP patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gu B, Yang Z, Du X, et al. Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial. J Nucl Med. 2024. PMID: 38272706. doi:10.2967/jnumed.123.266556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。